Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Hypotheses:
Primary: Increasing serum 25OHD from prevailing levels will significantly decrease
incidence of all types of cancer combined in a population sample of healthy postmenopausal
women.
Secondary:
1. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of
specific cancers: breast, lung, colon, myeloma, leukemia, lymphoma.
2. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of
other disorders, specifically hypertension, cardiovascular disease, osteoarthritis,
colonic adenomas, diabetes, upper respiratory infections and falls.
Specific Aims:
1. Determine the effect of supplementation with vitamin D3 on incidence of all types of
cancer combined.
2. Determine in a nested-case control study the association of serum 25OHD collected at
randomization and at the end of year one of study with risk of cancer over four years.
3. Sample randomly the population of healthy independently-living postmenopausal women 55
years and older from twelve adjacent rural counties in Nebraska.
4. Enroll a random sample of 2300 women into an intervention study, assign them randomly
to one of two treatment groups: 1) vitamin D3 (2000 IU/d) and calcium (1500 mg/d), or
2) vitamin D3 placebo and calcium placebo, and to follow each study participant for
four years.
5. Collect and store blood serum and white blood cells from every participant to test for
genetic markers should the intervention be found effective in decreasing the incidence
of cancer. Markers selected will be determined by the state of the science at the time
of analysis.
6. Determine the effect of supplementation with calcium and vitamin D3 on incidence of
specific cancers: breast, lung, colon, myeloma, leukemia, and lymphoma.
7. Determine the effect of supplementation on incidence of other disorders, specifically
hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper
respiratory infections, fractures, and falls.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
The primary outcome measure will be a cancer diagnosis.
5 years
No
United States: Institutional Review Board
CAPS08-15024
NCT01052051
June 2009
June 2015
Name | Location |
---|---|
Fremont Area Medical Center | Fremont, Nebraska 68025-2387 |